Qube Research & Technologies LTD Protalix Bio Therapeutics, Inc. Call Options Transaction History
Qube Research & Technologies LTD
- $62.3 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding PLX
# of Institutions
59Shares Held
5.7MCall Options Held
103KPut Options Held
4.6K-
Israel Englander Millennium Management LLC | New York, Ny811KShares$997,7260.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny805KShares$989,6580.0% of portfolio
-
Goldman Sachs Group Inc New York, NY462KShares$568,2080.0% of portfolio
-
Gsa Capital Partners LLP London, X0435KShares$535,3110.03% of portfolio
-
Northern Trust Corp Chicago, IL423KShares$520,5510.0% of portfolio
About Protalix BioTherapeutics, Inc.
- Ticker PLX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,753,400
- Market Cap $61.2M
- Description
- Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso fo...